Indian Pharma Companies Face Mixed Q2 Results Amid Pricing Pressure
· Business · Economic Times
India's pharmaceutical sector is bracing for a mixed performance in the September quarter due to rising raw material costs and increased generic competition. While companies like Sun Pharmaceutical Industries, Aurobindo Pharma, Torrent Pharmaceuticals, and Divi's Laboratories are expected to show strength, others face significant headwinds. Dr Reddy's Laboratories, Lupin, and Cipla are likely to struggle with pricing pressure and the absence of high-margin opportunities that bolstered their previous year's earnings. Sun Pharma's growth is supported by specialty products including Leqselvi, Unloxcyt, and Winlevi, alongside strong performance in emerging markets. Conversely, Dr Reddy's revenue growth is expected to remain flat as its North American business faces ongoing challenges.
Why it matters
Investors and stakeholders should monitor these results as they signal how major Indian drugmakers are navigating global competition and rising operational costs. The performance of these firms directly impacts the broader healthcare sector and market sentiment for pharmaceutical stocks in India.
Read the original report — Economic Times
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.